Bio-Techne Corp last reported quarterly results on Aug 12, 2026, for Q4 FY2026 (the quarter ended Jun 30, 2026): revenue of $321.2 million (+1.3% year over year) and diluted EPS of $0.35. It usually reports 35–43 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 4, 2026.
Results for Q1 FY2027, the quarter ending around Sep 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Nov 5, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–43 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 12, 2026
43 days after quarter end
|
Q4 FY2026
ended Jun 30, 2026
|
321
+1.3%
|
55
+409.0%
|
0.35
+408.0%
|
|
May 6, 2026
36 days after quarter end
|
Q3 FY2026
ended Mar 31, 2026
|
311
-1.5%
|
51
+126.0%
|
0.32
+128.6%
|
|
Feb 4, 2026
35 days after quarter end
|
Q2 FY2026
ended Dec 31, 2025
|
296
-0.4%
|
38
+8.9%
|
0.24
+9.1%
|
|
Nov 5, 2025
36 days after quarter end
|
Q1 FY2026
ended Sep 30, 2025
|
287
-1.0%
|
38
+13.6%
|
0.24
+14.3%
|
|
Aug 6, 2025
37 days after quarter end
|
Q4 FY2025
ended Jun 30, 2025
|
317
+3.5%
|
-18
-143.6%
|
-0.11
-144.7%
|
|
May 7, 2025
37 days after quarter end
|
Q3 FY2025
ended Mar 31, 2025
|
316
+4.2%
|
23
-54.0%
|
0.14
-54.8%
|
|
Feb 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Dec 31, 2024
|
297
+9.0%
|
35
+27.0%
|
0.22
+29.4%
|
|
Oct 30, 2024
30 days after quarter end
|
Q1 FY2025
ended Sep 30, 2024
|
289
+4.5%
|
34
-34.1%
|
0.21
-32.3%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TECH (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- MN
- Headquarters
- Minneapolis, MN
- SEC filer status
- Large accelerated filer
- SEC CIK
- 842023
- Former names
- TECHNE CORP /MN/ (until Oct 28, 2014)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.